Thrombosis reports with AstraZeneca vaccine not a cause for concern: TGA

The Therapeutic Goods Administration (TGA) is closely following reports of thromboembolic events with the AstraZeneca ChAdOx1-S COVID-19 vaccine that have led to its use being paused by many EU countries, but the regulator says there is no evidence of any excess risk or suggestion that anyone should avoid vaccination Last week countries including Norway, Denmark ...

Already a member?

Login to keep reading.

© 2021 the limbic